Onesource Specialty Pharma Limited · NSE:ONESOURCE
Onesource Specialty Pharma — Merger or Acquisition (September 2025)
11 slides from Onesource Specialty Pharma's merger presentation, Sep 26, 2025
Slide 1: Exchange filing cover letter for investor presentation
Corporate Office: Registered Office: Star 1, Opp IIM Bangalore, Bilekahalli, Cyber One, Unit No. 902, Sector 30A, Bannergha a Road, Bengaluru – Plot No - 4 & 6, Vashi, 560076, India Navi Mumbai - 400703, India T: +91 80 6784 0738 T: +91 22 2789 2924 F: +91 22 2789 2942 Date: September 26, 2025 BSE Limit
Slide 2: OneSource Board approves the previously announced strategic transaction
OneSource Board approves the previously announced strategic transaction, accelerating the company's global expansion and significantly strengthening its core positioning September 26, 2025
Slide 3: Safe Harbor Statement
Safe Harbor Statement Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "i
Slide 4: The OneSource Board has approved a strategic transaction to strengthen capabilities and capacity
The OneSource Board has approved a strategic transaction to strengthen the company's capabilities and capacity by acquiring the European CDMO business of Steriscience and anti-infective business from Brooks Steriscience OneSource Creation (Phase 1) OneSource Expansion (Phase 2) Consolidation of grou
Slide 5: Augmenting value proposition, upgraded FY28 outlook of $500+M revenue and 40% EBITDA
OneSource is augmenting its value proposition through strategic diversification and new capabilities, leading to an upgraded FY28 outlook of $500+M revenue and 40% EBITDA Transaction to lead OneSource to raise its FY28 financial outlook Scale • EU based sterile fill finish USFDA approved site with m
Slide 6: European business from Steriscience adds scale; Indian asset adds anti-infective capabilities
The European business from Steriscience adds scale and offers a de-risked platform for our DDCs, while the Indian asset provides powerful, complementary anti-infective capabilities Steriscience, Poland Brooks Steriscience , Vadodara, India • Capabilities in biologics and complex injectables across d
Slide 7: Transaction values OneSource at $2.7 billion, an 18.6% premium
Transaction values OneSource at $2.7 billion, a 18.6% premium to the last closing price*, incoming assets valued at a relative discount to OneSource Enterprise Value ($m) Equity Value ($m) Price Per Share Total shares post closing ~140.64 (million) 2,826 2,745 2,121 OneSource Total Dilution for OneS
Slide 8: The scheme will take up to 15 months to close
The scheme will take up to 15 months to close The Independent sub-committee (Dr. Claudio Albrecht, Colin Michael Bond Scheme Effective, fixing Record Date and Issuance of Shares and Vijay Karwal) was constituted to review the proposed scheme Full Board approving the scheme with the promoters recusin
Slide 9: Resultant shareholding post-transaction
Resultant shareholding post-transaction Pre-Scheme Post-Scheme* Promoter and Promoter Group ~30% ~36% Others ~70% ~64% Total 100% 100% *For Steriscience Specialities Private Limited (SSPL), prior to effectiveness of the Scheme, there are some share transfers proposed among promoter/ non-promoters. F
Slide 10: Advisors to the transaction
Advisors to the transaction Fairness Opinion on Valuation Transaction Advisors 8
Slide 11: Get in touch with us
Get in touch with us REGISTERED AND CORPORATE OFFICE INVESTOR RELATIONS OneSource Specialty Pharma Ltd Investor-relations@onesourcecdmo.com Registered Office: Unit No. 902, Cyber One, Plot No - 4 & 6, Sector 30A, Vashi, Navi Mumbai, Sanpada, Thane, Maharashtra, India, 400703 T: +91 22 2789 2924 F: +
OneSource Specialty Pharma — Merger or Acquisition (September 2025) on 6ix